Cepheid Reaches New 12-Month High at $47.21 (CPHD)
Cepheid (NASDAQ:CPHD)’s share price reached a new 52-week high during trading on Thursday, StockRatingsNetwork.com reports. The stock traded as high as $47.21 and last traded at $46.68, with a volume of 216,385 shares traded. The stock had previously closed at $46.31.
A number of analysts have recently weighed in on CPHD shares. Analysts at JPMorgan Chase & Co. downgraded shares of Cepheid from an “overweight” rating to a “neutral” rating in a research note to investors on Tuesday. Separately, analysts at Needham & Company initiated coverage on shares of Cepheid in a research note to investors on Thursday, December 19th. They set a “hold” rating on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Cepheid in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $43.26.
In other Cepheid news, EVP Kerry Flom unloaded 6,357 shares of the stock on the open market in a transaction dated Friday, January 3rd. The stock was sold at an average price of $45.66, for a total value of $290,260.62. Following the sale, the executive vice president now directly owns 20,000 shares of the company’s stock, valued at approximately $913,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Cepheid has a one year low of $30.95 and a one year high of $47.21. The stock’s 50-day moving average is $45.53 and its 200-day moving average is $39.3. The company’s market cap is $3.167 billion.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.